Chi-Med's Lead Candidate Passes Phase III Colorectal Cancer Test

Hutchison China MediTech (Chi-Med) reported that its lead drug, fruquintinib, met its endpoints in a pivotal Phase III China trial. Fruquintinib was tested as a third-line treatment for metastatic colorectal cancer. Chi-Med, which has partnered the drug with Lilly , is now preparing to file for CFDA approval. The company said fruquintinib met both overall and progression-free survival in the heavily pre-treated patient population, though it is saving specific data for the mid-2017 ASCO meeting. Fruquintinib, a VEGFR inhibitor, has an anti-angiogenic mechanism. More details.... Stock Symbols: (AIM/NSDQ: HCM) (NYSE: LLY) Share this with colleagues: // //